# E-DRUG: AZT trials in developing countries **URL:** \ **Category:** e-drug\ **Created:** [October 20, 1997, 4:08pm UTC](https://talk.edrugplus.org/t/e-drug-azt-trials-in-developing-countries/1560 "1997-10-20T16:08:30Z")\ **Posts on this page:** 1\ **Page:** 1
**Author:** ![Dr\_Elena\_Yu\_Ph.D\_MPH](https://avatars.discourse-cdn.com/v4/letter/d/c2a13f/32.png) [@Dr\_Elena\_Yu\_Ph.D\_MPH](https://talk.edrugplus.org/u/Dr_Elena_Yu_Ph.D_MPH)\ **Post date:** [October 20, 1997, 4:08pm UTC](https://talk.edrugplus.org/t/e-drug-azt-trials-in-developing-countries/1560/1 "1997-10-20T16:08:30Z")
E-DRUG: AZT trials in developing countries (contd.) --------------------------------------------------- I have two questions which I hope someone could help me: (1) Aside from going on MEDLINE, can somone point me to some succinctly written documentation as to which of the 15-some AZT trials going on in Africa are in which phases? (Phase I, Phase II, Phase III, or Phase IV trials). (2) If we rule out cost, is there any scientific reason why the "lose-dose" short treatment of AZT which David Ho spoke about in his Time Magazine opinion piece (Sept 29, 1997) cannot be compared to a "standard" (since 1994) AZT treatment? Experimentation with lowered dosages of drugs have occurred in the past. The oral contraceptives are an example. Assuming the cost is not an issue, is there any scientific reasons why a low-dose could not be compared to the "full treatment"? Would there be an ethical problem doing such a clinical trial (omitting the placebo group)? Thank you. Elena Yu, Ph.D., MPH Professor Division of Epidemiology and Biostatistics Graduate School of Public Health San Diego State University San Diego, CA 92182 Phone: (619) 594-2711 Fax: (619) 594-6112 e-mail: eyu@mail.sdsu.edu Note from the moderator: ------------------------ Dr. David Ho, an expert in AIDS/HIV was one of the two members of the editorial board of the New England Journal of Medicine who resigned last week because of disagreement with the editorial which accompanied the article by Drs. Peter Lurie and Sidney Wolfe referred to earlier in E-DRUG. Syed Rizwanuddin Ahmad -- Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'. Mail administrative requests to `majordomo@usa.healthnet.org'. For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.